Treatment of metastatic urothelial cancer in the post-MVAC era.
The combination of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) has become the standard of care for metastatic urothelial cancer. Its efficacy has been proven in this setting but it can be a difficult regimen to tolerate. With the introduction of new active agents, different combinations are being evaluated. This article will highlight the use of these new regimens with emphasis on those employing gemcitabine or the taxanes.
Cohen
E E
EE
Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, Illinois, USA.
Stadler
W M
WM
D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use*; D004317:Doxorubicin / Q000627:therapeutic use*; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use*; D019042:Muscle Neoplasms / Q000188:drug therapy* / Q000556:secondary; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology; D019459:Urothelium / Q000473:pathology; D014747:Vinblastine / Q000627:therapeutic use*; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D014747:Vinblastine; D004317:Doxorubicin; D002945:Cisplatin; D008727:Methotrexate; D000093542:Gemcitabine